Abstract
The insulin-like growth factor (IGF) system has been implicated in many times of cancer. Upon ligand binding, the type I IGF receptor (IGF1R) transmembrane tyrosine kinase receptor is activated and serves to activate multiple downstream signaling targets. Multiple drugs have been developed to disrupt the function of this receptor, but to date the clinical trial results have been disappointing.
| Original language | English (US) |
|---|---|
| Title of host publication | Cancer Therapeutic Targets |
| Publisher | Springer New York |
| Pages | 823-829 |
| Number of pages | 7 |
| Volume | 2-2 |
| ISBN (Electronic) | 9781441907172 |
| ISBN (Print) | 9781441907165 |
| DOIs | |
| State | Published - Jan 1 2017 |
Keywords
- Breast cancer
- Clinical trials
- Ewing's sarcoma
- Fibroblast cells
- Functional IGF1R
- IGF-II
- Monoclonal antibodies
- Multianalyte molecular techniques
- TKIs
- Type I insulin-like growth factor receptor (IGF1R)
- Tyrosine kinase inhibitors (TKIs)
- mRNA expression and protein levels
- ras/raf/MEK/MAPK and PI3K/Akt/mTORC1 signaling cascades
